Gilead Sciences (NASDAQ:GILD) CEO John Milligan made the audience laugh at the Barclays healthcare conference on Tuesday. Barclays analyst Geoff Meacham referenced a letter he had sent to Gilead’s management team urging the company to take steps to increase its valuation, including making transformational acquisitions. Milligan’s response was perfectly timed: “There was a letter?”
